sST2 对慢性心力衰竭患者预后评价的研究进展

杨潇 晗1, 张 琦2
1.河北医科大学 2.唐山市工人医院

摘要

目的:慢性心力衰竭是全球关注的健康问题。全身性治疗后，慢性心衰患者仍易复发，预后不良,部分患者甚至面临死亡结局。借助客观工具全面评价患者预后、降低死亡风险已成为当下临床研究的热点。新型生物标志物可溶性生长刺激表达基因 2 蛋白（sST2）近年来表现出的在预后方面的潜能和独特的优势使其备受关注，并被列入多个指南。本文就 sST2 对慢性心力衰竭患者预后评价的研究进展进行综述。

关键词

sST2 慢性心力衰竭 预后评价 研究进展

参考

[1] de Boer RA, Daniels LB, Maisel AS, Januzzi JL Jr.State of the Art: Newer biomarkers in heart failure.Eur J Heart Fail. 2015; 17(6): 559–69. [2]Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S,Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation.(2002) 106:2961 – 6. doi:10.1161/01.CIR. 0000038705.69871.D9 [3]Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. (2007) 117:1538–49. doi:10.1172/JCI30634 [4]Balion CM, Santaguida P , McKelvie R, et al. Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. Clin Biochem 2008; 41: 231-9. [5] W.C. Meijers, et al., Variability of biomarkers in patients with chronic heart failure and healthy controls, Eur. J. Heart Fail. 19 (2017) 357–365, https://doi.org/10.1002/ejhf.669. [6] A. Bayes-Genis, E. Zamora, M. de Antonio, A. Galán, J. Vila, A. Urrutia, C. Díez,R. Coll, S. Altimir, J. Lupón, Soluble ST2 serum concentration and renal function in heart failure, J. Card. Fail. 19 (2013) 768–775, https://doi.org/10.1016/j.cardfail.2013.09.005. [7]Weinberg EO, Shimpo M, Hurwitz S, et al.Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721–6. [8]Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ: Heart Fail. 2011;4:180- - -7. [9]Zilinski JL, Shah RV, Gaggin HK, et al. Mea-surement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care 2012;16:R135. [10]Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation2012;126:1596-604. [11]Wu AHB, Wians F , Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results. Am Heart J.(2013)165:995-9. doi:10.1016/j.ahj.2013.02.029 [12] W.J. Paulus, C. Tschöpe, A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation, J. Am. Coll. Cardiol. 62 (2013)263 – 271, https:// doi.org/10.1016/j.jacc.2013.02.092. [13]O.F. AbouEzzeddine, P.M. McKie, S.M. Dunlay, S.R. Stevens, G.M. Felker,B.A. Borlaug, H.H. Chen, R.P. Tracy, E. Braunwald, M.M. Redfield, Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction, J. Am. Heart Assoc. 6 (2017), https://doi.org/ 10.1161/JAHA.116.004382. [14] Pascual-Figal DA, Bayes-Genis A, Asensio-Lopez MC, et al. The interleukin-1 axis and risk of death in patients with acutelydecompensated heart failure. J Am Coll Cardiol 2019;73:1016–25. [15] Aimo A, Maisel AS, Castiglione V, et al. sST2 for outcome prediction in acute heart failure:which is the best cut-off? J Am Coll Cardiol 2019;74:478–9. [16]Y ancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. (2013) 128:e240–327. doi: 10.1161/CIR.0b013e 31829e8776 [17]Yancy CW , Jessup M, Bozkurt B, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2013;62:e147-239. [18] E. Najjar, U.L. Faxén, C. Hage, E. Donal, J.-C. Daubert, C. Linde, L.H. Lund, ST2 in heart failure with preserved and reduced ejection fraction, Scand. Cardiovasc. J. [19]FDA. Substantial Equivalence Determination Decision Summary Assay Only Template 2020[cited 202017/07/2020]. Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K111452.pdf. [20] Moliner P , Lupón J, Barallat J et al. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. Int J Cardiol 2018;257:188–92. [21]Maass AH, Vernooy K, Wijers SC. van’t Sant J, Cramer MJ, Meine M, et .Refining success of cardiac resynchronization therapy using a simple score predicting the amount of reverse ventricular remodelling: results from the Markers and Response to CRT (MARC) study. EP Europace. (2018) 20:e1–10. doi: 10.1093/europace/euw445 [22]Levy D, Larson MG, Vasan RS, Kannel WB,Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557–62. [23]D.B. Ojji, S. Lecour, O.M. Adeyemi, K. Sliwa, Soluble ST2 correlates with some indicators of right ventricular function in hypertensive heart failure, Vasc. Health Risk Manag. 13 (2017) 311–316, https://doi.org/10.2147/VHRM.S127430. [24]F. Cosentino, P. J. Grant, V. Aboyans et al., “2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD,” European Heart Journal, vol. 41, no. 2, pp. 255–323, 2020. [25]Ruocco G, Palazzuoli A, Ter Maaten JM, et al. Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney. Crit Care.2015;19(1):296-118, doi:10.1186/s13054-015-1017-3, indexed in Pubmed:26335137. [26]M. Plawecki, M. Morena, N. Kuster, L. Chenine, H. Leray-Moragues, B. Jover,P. Fesler, M. Lotierzo, A.-M. Dupuy, K. Klouche, J.-P. Cristol, sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling: impact on risk prediction, Mediators Inflamm. 2018 (2018) 1 – 9, https://doi.org/ 10.1155/2018/3952526. 第一作者简介：姓名：杨潇晗，性别：女，民族：汉族，出生年月：1997 年 1 月，籍贯：河北保定，学历：研究生，研究方向：心血管内科